Published in Diabetes Obes Metab on June 01, 2010
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol (2012) 1.60
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care (2013) 1.51
Cardiovascular effects of gliptins. Nat Rev Cardiol (2013) 1.23
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf (2014) 1.18
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol (2013) 1.17
Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care (2011) 1.15
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag (2012) 1.07
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol (2012) 1.05
Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther (2012) 1.02
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci (2012) 1.01
Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract (2013) 1.00
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag (2011) 1.00
The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. Adv Ther (2013) 0.98
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol (2014) 0.87
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol (2015) 0.85
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes Metab J (2015) 0.83
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol (2016) 0.81
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes (2013) 0.80
Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Ther Adv Endocrinol Metab (2013) 0.80
Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf (2015) 0.79
Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther (2013) 0.79
Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther Clin Risk Manag (2013) 0.79
Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? Biomed Res Int (2015) 0.78
The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus. J Diabetes Res (2013) 0.77
Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. Clin Diabetes (2014) 0.77
Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLoS One (2016) 0.77
Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study. Vasc Health Risk Manag (2015) 0.76
Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients. J Cardiovasc Ultrasound (2015) 0.76
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother (2016) 0.76
Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. Vasc Health Risk Manag (2013) 0.75
Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data. Diabetes Ther (2014) 0.75
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Adv Ther (2016) 0.75
Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World J Diabetes (2015) 0.75
Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf (2016) 0.75
Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin. J Drug Assess (2016) 0.75
Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med (1993) 6.89
Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia (2000) 3.63
The Xenopus protein kinase pEg2 associates with the centrosome in a cell cycle-dependent manner, binds to the spindle microtubules and is involved in bipolar mitotic spindle assembly. J Cell Sci (1998) 2.67
Cloning by differential screening of a Xenopus cDNA coding for a protein highly homologous to cdc2. Proc Natl Acad Sci U S A (1991) 2.60
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab (2009) 2.04
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia (2007) 2.01
Cloning by differential screening of a Xenopus cDNA that encodes a kinesin-related protein. Mol Cell Biol (1991) 1.95
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia (2006) 1.89
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab (2011) 1.87
Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest (1987) 1.83
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab (2005) 1.76
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab (2010) 1.76
A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia (1995) 1.70
Diastolic dysfunction is predictive of difficult weaning from cardiopulmonary bypass. Anesth Analg (2001) 1.65
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab (2007) 1.61
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab (2010) 1.59
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab (2008) 1.58
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab (2007) 1.58
The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1999) 1.58
Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res (2007) 1.55
Mechanism of insulin-resistant glucose transport activity in the enlarged adipose cell of the aged, obese rat. J Clin Invest (1982) 1.51
Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia (2005) 1.51
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Eur Heart J (2002) 1.50
In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. J Clin Invest (1983) 1.50
Two related strains of feline infectious peritonitis virus isolated from immunocompromised cats infected with a feline enteric coronavirus. J Clin Microbiol (1996) 1.46
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med (2007) 1.43
Amplification of ehrlichial DNA from dogs 34 months after infection with Ehrlichia canis. J Clin Microbiol (1998) 1.42
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab (2011) 1.38
Changes in the polyadenylation of specific stable RNA during the early development of Xenopus laevis. Gene (1988) 1.38
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med (2008) 1.37
The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol (1994) 1.37
Comparison of the nucleotide sequences of 16S rRNA, 444 Ep-ank, and groESL heat shock operon genes in naturally occurring Ehrlichia equi and human granulocytic ehrlichiosis agent isolates from Northern California. J Clin Microbiol (2000) 1.36
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab (2008) 1.33
Outcome with high blood lactate levels during cardiopulmonary bypass in adult cardiac operation. Ann Thorac Surg (2000) 1.32
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab (2011) 1.32
Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21--q23 and is associated with a common polymorphism in LMNA in Pima Indians. Mol Genet Metab (2001) 1.32
Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians. J Clin Invest (1984) 1.32
Canine granulocytic anaplasmosis: a review. J Vet Intern Med (2009) 1.29
Common virus infections in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus. J Feline Med Surg (2004) 1.27
Rate-limiting steps for insulin-mediated glucose uptake into perfused rat hindlimb. Am J Physiol (1986) 1.25
The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. J Biol Chem (1983) 1.23
Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol (2000) 1.22
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab (2007) 1.22
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res (2008) 1.19
Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab (2001) 1.19
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res (2008) 1.19
Aortic valve endocarditis in a dog due to Bartonella clarridgeiae. J Clin Microbiol (2001) 1.18
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl (2008) 1.17
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab (2009) 1.14
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab (2007) 1.11
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab (2011) 1.11
Insulin binding and hexose transport in rat adipocytes. Relation to cell size. Diabetologia (1980) 1.05
Serologic and molecular evidence of Ehrlichia spp. in coyotes in California. J Wildl Dis (2000) 1.02
Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res (2008) 1.02
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia (2013) 1.02
Xenopus cyclin E, a nuclear phosphoprotein, accumulates when oocytes gain the ability to initiate DNA replication. J Cell Sci (1996) 1.01
Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-dependent diabetics. Measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes. J Clin Invest (1983) 1.00
Rate-limiting steps of 2-deoxyglucose uptake in rat adipocytes. Biochim Biophys Acta (1980) 1.00
Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract (2013) 1.00
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab (2008) 1.00
Complex genetic predisposition to cancer in an extended HNPCC family with an ancestral hMLH1 mutation. J Med Genet (1996) 0.99
Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter. Genomics (1998) 0.98
Impact of social support, cynical hostility and anger expression on progression of coronary atherosclerosis. J Am Coll Cardiol (2000) 0.97
Glucose 6-phosphate effects on deoxyglucose, glucose and methylglucose transport in rat adipocytes. Evidence for intracellular regulation of sugar transport by glucose metabolites. Biochim Biophys Acta (1984) 0.97
Insulin sensitivity in adipocytes from subjects with varying degrees of glucose tolerance. Am J Physiol (1986) 0.97
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab (2014) 0.97
Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial. Arterioscler Thromb Vasc Biol (2001) 0.96
Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol (1999) 0.96
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res (2007) 0.95
Intracellular glucose concentration in small and large rat adipose cells. Am J Physiol (1980) 0.95
Regulation of plasma lactate concentration in resting human subjects. Metabolism (1990) 0.95
Glucose transport in isolated rat adipocytes with measurements of L-arabinose uptake. Am J Physiol (1978) 0.94
Accumulation of 2-deoxyglucose against its concentration gradient in rat adipocytes. Biochim Biophys Acta (1981) 0.94
Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin (2010) 0.93
Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate). Br J Clin Pharmacol (1979) 0.93
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care (2001) 0.92
Systematic off-pump coronary artery revascularization in multivessel disease: experience of three hundred cases. J Thorac Cardiovasc Surg (2000) 0.92
Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol (1998) 0.92
Excess of hMLH1 germline mutations in Swiss families with hereditary non-polyposis colorectal cancer. Int J Cancer (1998) 0.92
Effects of dietary composition on glucose metabolism in rat adipose cells. Am J Physiol (1981) 0.91
Acarologic risk of exposure to emerging tick-borne bacterial pathogens in a semirural community in northern California. Vector Borne Zoonotic Dis (2001) 0.90
Time-course effect of exercise-induced muscle damage on localized muscle mechanical properties assessed using elastography. Acta Physiol (Oxf) (2014) 0.90
Bartonella henselae antibody prevalence in free-ranging and captive wild felids from California. J Wildl Dis (1998) 0.89